BioSante Pharmaceuticals Signs Bio-E-Gel(R) Marketing Agreement With Bradley Pharmaceuticals, Inc.
08 Novembre 2006 - 1:45PM
Business Wire
BioSante Pharmaceuticals, Inc. (Amex:BPA) today announced that it
has signed an exclusive agreement with Bradley Pharmaceuticals,
Inc. (NYSE:BDY) for the marketing of Bio-E-Gel� (transdermal
estradiol gel) in the United States. Upon execution of the
agreement, BioSante received $2.625 million. Additional regulatory
and sales based milestone payments could bring the total of such
payments from Bradley to BioSante to more than $40 million. In
addition, Bradley has agreed to pay to BioSante royalties on sales
of Bio-E-Gel, if and when Bio-E-Gel is approved by the U.S. Food
and Drug Administration (FDA) and marketed by Bradley. Bio-E-Gel is
currently being reviewed by the FDA. BioSante submitted the
Bio-E-Gel new drug application (NDA) in February 2006. Bradley,
through its Kenwood Therapeutics division, has agreed to market
Bio-E-Gel and target estrogen prescribing physicians in the U.S.
comprised mostly of gynecologists with at least 49 Kenwood sales
representatives. The total amount of the up-front and milestone
payments mentioned above is net of BioSante�s obligations to
Antares Pharma, BioSante�s licensor of the transdermal estradiol
gel formulation in Bio-E-Gel. �We are excited to have met another
milestone toward our planned commercial launch of Bio-E-Gel,� said
Stephen M. Simes, president & CEO of BioSante. �We believe
Bradley is an excellent mid-sized specialty pharmaceutical company
to market Bio-E-Gel and that Bradley is in an excellent position to
capture a share of the U.S. estrogen therapy market, which is
currently estimated at approximately $1.3 billion in annual sales,
of which the transdermal segment, mostly patches, is about $250
million. We look forward to working with Bradley toward a
successful launch of Bio-E-Gel in 2007.� Dan Glassman, president
& CEO of Bradley said, �We are impressed with the clinical
results of the Bio-E-Gel development program and we believe
Bio-E-Gel and its low dose regimen will be an attractive
alternative for physicians who treat and for women who suffer from
menopausal symptoms.� About Bio-E-Gel� Bio-E-Gel is a fast-drying
gel formulation of estradiol, the same estrogen produced naturally
in women. Bio-E-Gel was developed to be absorbed through the skin
after topical application on the upper arm, and delivers estradiol
to the bloodstream evenly over time in a non-irritating, painless
manner. Bio-E-Gel is administered using a metered dose applicator
that delivers 0.87 g of gel per actuation, thereby allowing for
precise titration from dose to dose. The gel dries quickly in one
to two minutes. A 12-week, double-blind, placebo-controlled Phase
III study of 484 symptomatic menopausal women was designed to
identify the lowest effective dose to allow estrogen treatment in
the safest possible manner. The lead investigator for the
multicenter study was Dr. James A. Simon, director of the Women's
Health Research Center in Washington, D.C. The women in the study
were randomly assigned to one of four treatment arms: low-dose
(0.87 g), mid-dose (1.7 g) or high-dose (2.6 g) of Bio-E-Gel, or
matching placebo. The U.S. Food & Drug Administration (FDA)
defined endpoints were a significant decrease over placebo in both
the number and severity of hot flashes at week 4 and week 12 of
treatment. Study results showed a clear dose response in the
reduction in the number and severity of hot flashes in the low,
mid, and high doses tested. The most effective Bio-E-Gel dose
decreased the number of hot flashes by 85 percent by 12 weeks of
treatment, from 12.9 hot flashes per day at baseline to 1.6 per day
at the end of the 3 month study. The decrease compared to placebo
treatment was significant (p
Biosante Pharma (AMEX:BPA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Biosante Pharma (AMEX:BPA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Biosante Pharmaceuticals (American Stock Exchange): 0 recent articles
Plus d'articles sur BioSante Pharmaceuticals, Inc.